![]() | Up a level |
2018
Cohen, J. B., Engert, A., Ansell, S. M., Younes, A., Trneny, M., Savage, K. J., Ramchandren, R., Collins, G. P., Fanale, M. A., Armand, P., Zinzani, P. L., de Boer, J. P., Shipp, M. A., Santoro, A., Timmerman, J. M., Sacchi, M., Sy, O. and Kuruvilla, J. (2018). Nivolumab Treatment Beyond Investigator-Assessed Progression: Outcomes in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma From the Phase 2 CheckMate 205 Study. Br. J. Haematol., 181. S. 87 - 89. HOBOKEN: WILEY. ISSN 1365-2141
2017
Engert, A., Fanale, M., Santoro, A., Armand, P., Ansell, S., Zinzani, P. L., Timmerman, J., Collins, G., Ramchandren, R., Cohen, J., De Boer, J. P., Kuruvilla, J., Savage, K., Trneny, M., Rodig, S., Shipp, M., Kato, K., Sumbul, A., Farsaci, B. and Younes, A. (2017). NIVOLUMAB FOR RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA AFTER AUTOLOGOUS TRANSPLANT: FULL RESULTS AFTER EXTENDED FOLLOW-UP OF THE MULTICOHORT MULTICENTER PHASE 2 CHECKMATE 205 TRIAL. Haematologica, 102. S. 145 - 146. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Jaeger, U., Engert, A., Fanale, M., Santoro, A., Armand, P., Ansell, S., Zinzani, P. L., Timmerman, J. M., Collins, G. P., Ramchandren, R., Cohen, J. B., De Boer, J. P., Kuruvilla, J., Savage, K. J., Trneny, M., Rodig, S., Shipp, M., Kato, K., Sumbul, A., Farsaci, B. and Younes, A. (2017). Nivolumab for relapsed/refractory classical Hodgkin lymphoma after autologous transplantation: full results after extended follow-up of the multicohort, multicenter phase 2 CheckMate 205 trial. Oncol. Res. Treat., 40. S. 13 - 15. BASEL: KARGER. ISSN 2296-5262
2016
Engert, A., Santoro, A., Shipp, M., Zinzani, P. L., Timmerman, J., Ansell, S., Armand, P., Fanale, M., Ratanatharathorn, V., Kuruvilla, J., Cohen, J., Collins, G., Savage, K., Trneny, M., Kato, K., Farsaci, B., Parker, S., Rodig, S. and Younes, A. (2016). CHECKMATE 205: A PHASE 2 STUDY OF NIVOLUMAB IN PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA FOLLOWING AUTOLOGOUS STEM CELL TRANSPLANTATION AND BRENTUXIMAB VEDOTIN. Haematologica, 101. S. 319 - 320. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Moskowitz, C., Zinzani, P. L., Fanale, M. A., Armand, P., Johnson, N., Ribrag, V., Radford, J., von Tresckow, B., Tomita, A., Shipp, M., Wang, Y., Ricart, A. D., Balakumaran, A. and Chen, R. (2016). PEMBROLIZUMAB FOR RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA: MULTICOHORT, PHASE 2 KEYNOTE-087 STUDY. Haematologica, 101. S. 44 - 45. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Moskowitz, C., Zinzani, P. L., Fanale, M. A., Armand, P., Johnson, N., Ribrag, V., Radford, J., von Tresckow, B., Tomita, A., Shipp, M. A., Wang, Y., Ricart, A. D., Balakumaran, A. and Chen, R. (2016). MULTICOHORT PHASE 2 STUDY OF PEMBROLIZUMAB FOR RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA (R/R CHL): KEYNOTE-087. Haematologica, 101. S. 319 - 320. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Zinzani, P. L., Engert, A., Younes, A., Santoro, A., Ansell, S., Timmerman, J., Collins, G., Armand, P., Savage, K. J., Trneny, M., Fanale, M., Kuruvilla, J., Cohen, J. B., Shipp, M., Rodig, S., Kato, K., Sumbul, A., Farsaci, B. A. and Ratanatharathorn, V. (2016). CHECKMATE 205 COHORT C: NIVOLUMAB IN PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA AFTER PRIOR BRENTUXIMAB VEDOTIN AND AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION. Haematologica, 101. S. 43 - 45. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Zinzani, P. L., Sasse, S., Radford, J., Gautam, A. and Bonthapally, V. (2016). Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma: An updated review of published data from the named patient program. Crit. Rev. Oncol./Hematol., 104. S. 65 - 71. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1879-0461
2015
Zinzani, P. L., Sasse, S., Radford, J., Shonukan, O. and Bonthapally, V. (2015). Experience of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma and relapsed/refractory systemic anaplastic large-cell lymphoma in the Named Patient Program: Review of the literature. Crit. Rev. Oncol./Hematol., 95 (3). S. 359 - 370. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1879-0461
2014
Oki, Y., Buglio, D., Zhang, J., Ying, Y., Zhou, S., Sureda, A., Ben-Yehuda, D., Zinzani, P. L., Prince, H. M., Harrison, S. J., Kirschbaum, M., Johnston, P. B., Shen, A., von Tresckow, B. and Younes, A. (2014). Immune regulatory effects of panobinostat in patients with Hodgkin lymphoma through modulation of serum cytokine levels and T-cell PD1 expression. Blood Cancer J., 4. LONDON: NATURE PUBLISHING GROUP. ISSN 2044-5385
2010
Hallek, M., Fischer, K., Fingerle-Rowson, G., Fink, A. M., Busch, R., Mayer, J., Hensel, M., Hopfinger, G., Hess, G., von Gruenhagen, U., Bergmann, M., Catalano, J., Zinzani, P. L., Caligaris-Cappio, F., Seymour, J. F., Berrebi, A., Jaeger, U., Cazin, B., Trneny, M., Westermann, A., Wendtner, C. M., Eichhorst, B. F., Staib, P., Buehler, A., Winkler, D., Zenz, T., Boettcher, S., Ritgen, M., Mendila, M., Kneba, M., Doehner, H. and Stilgenbauer, S. (2010). Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet, 376 (9747). S. 1164 - 1175. NEW YORK: ELSEVIER SCIENCE INC. ISSN 0140-6736